Market Reports

Developing innovative antivirals for novel viruses

Since the emergence of COVID-19, researchers worldwide have striven to study and overcome this new disease and the novel coronavirus (SARS-CoV-2) that causes it. To achieve this, we will probably need both vaccines and antiviral drugs, report Zamas Lam, Senior Vice President of Preclinical Development, and John Kolman, Vice President of Translational Medicine, QPS

Scaling-up the pharmaceutical supply chain with digitisation: part I

If there are issues with any vaccine, the traditional recall process, which is highly dependent on manual and paper-based processes — and provides no insight in terms of where the product ends up — is not up to the task. It is simply too slow and ill-informed to combat the fallout!

Cleanroom Conference and Manufacturing Chemist Live 2020 to go virtual

The virtual event taking place on 10-11 November 2020 will provide delegates with full access to the Manufacturing Chemist Live, Cleanroom UK, India and Singapore content and exhibitors

Transporting the COVID-19 vaccine around the world: a global problem

Elisabeth Vachette, Head of Product Management for Bags/Mixing/Tanks at Sartorius Stedim Biotech, discusses the challenges associated with distributing a vaccine to the global population with Dr Kevin Robinson

Manufacturing pressure accelerates move to fully formulated film coatings

Why now is the right time to change to a leaner system, explains Colorcon's Dr Jason Teckoe, Technical Director, EMEA

Small test efforts for large production facilities

Sanofi uses filling and closing machines from Syntegon Technology to determine the ideal manufacturing parameters for the development and lifecycle management of its products, explains Sebastian Lauterbach, Area Sales Manager, Syntegon Technology

Cleanroom Conference and Manufacturing Chemist Live events set to go ahead

The co-located events will go ahead in October with new safety measures in place, after being postponed from their original date at the start of summer due to COVID-19

Delivering success for inhaled drug development programmes

No two inhaled drug development programmes will have exactly the same characteristics or drivers; so, to ensure the greatest chance of success, it is important not to be unduly influenced by previous programme, or have a technology bias towards a single platform

Next-generation rapid transfer systems for the biopharmaceutical industry

The safe manufacture of pharmaceutical drugs requires perfectly sterile and particle-free environments. A rapid transfer port, which comprises double containment doors that are integrated into an isolator, is a system that allows the safe transfer of substances used in drug development, such as active pharmaceutical ingredients or vaccines

Overcoming the excipient challenge with a multifunctional filler-binder

Dr Maj-Britt Cepok, Head of Business Development Pharma at BENEO, talks to Dr Kevin Robinson about trends in excipients and explains why the right filler-binder can make all the difference

Isolator transfer design for ATMP products

A challenge posed by the increase of closed systems is the transfer of semi-finished products without losing the aseptic conditions required by regulations. A new study has tested a transfer system aiming to offer biocontainment without losing cell viability of ATMP products

Enhancing clinical trial supply with JTM: part II

In a constantly changing world, the pharmaceutical industry is having to adopt its practices to serve the needs of a rapidly growing and ageing population and develop innovative personalised medicines. Almac has responded to these demands with a Just-in-Time Manufacturing solution that fulfils the requirements of a high value, time sensitive clinical supply chain. Dr Kevin Robinson spoke to Natalie Balanovsky, Just-in-Time Manufacturing Solutions Manager, and Mark Rohlfing, Vice President of Operations, to find out more

Next-generation pharmaceutical spray drying

Lonza's Kimberly B. Shepard, Associate Principal Engineer, and Michael M. Morgen, Associate Director, R&D, discuss mechanistic process development with high-performance polymers for bioavailability enhancement

Reading and understanding vendor-supplied tablet drawings

Understanding the tablet drawings supplied by tooling vendors is a meaningful way to learn more about your product, reports John Norman, Technical Service Representative, Natoli Engineering Company

Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain

The pharmaceutical industry has responded extremely well to the coronavirus pandemic. At the same time, the industry is changing before our eyes. To put it in simple terms, there will be no more “business-as-usual” in pharmaceutical manufacturing after COVID-19, explains Andrew Badrot, CEO, C2 PHARMA

A pivotal time for pharma's global biotechnology industry

In these uncertain times, GEA, the globally active mechanical and plant engineering company, is taking its role in the fight against the coronavirus — and any other — epidemic, extremely seriously. Committed to “Engineering for a better world,” GEA designs and builds modular plant and fully integrated systems help to bring new treatments to market in the shortest possible time

Accelerating vaccine development with AI

Despite the tremendous advances in medical science in recent decades, there is still so much about the human body that we’re yet to discover, reports Billy Sisk, Life Sciences Industry Manager, EMEA, Rockwell Automation

How to comply with FDA-imposed nitrosamine impurity testing

The detection of nitrosamine impurities in commercially available drugs has recently prompted the US FDA to issue multiple product recalls and mandate additional testing to safeguard consumer health and safety; Michael Walker, Technical Expert at Intertek Pharmaceutical Services, and Jon Bardsley, Vertical Marketing Specialist, Pharma and BioPharma, Thermo Fisher Scientific, report

Excipient innovation for enhanced patient compliance: part II

Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing

Future-proof DMPK studies for next-generation therapeutics

SCIEX's Lei Xiong, Rolf Kern and Elliott Jones explain the top five reasons why you can’t count on ligand-binding assays to study the drug metabolism and pharmacokinetics of biologics

Tackling coronavirus with AI-derived combination drug products: Part I

The ongoing spread of COVID-19 is risking the lives of millions of rare disease patients around the world. Dr David Brown, Chairman and cofounder of Healx, believes the company’s data-driven AI platform is perfectly positioned to support the efforts to find effective treatments and, within weeks, predict which known drugs can be repurposed to treat other conditions

New date announced for Manufacturing Chemist Live

The inaugural conference will now take place on 28-29 October 2020

Excipient innovation for enhanced patient compliance: part I

Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing

Sustainability and innovation in the complex combination therapy sector

The patient and commercial benefits of bringing new drugs to market in the shortest possible time are well recognised; potential methodologies to reduce the development cycle and accelerate drug product approvals are constantly being explored. As a result, other targets, including the environmental efficacy of a therapy, have traditionally been a distant, secondary objective. Bespak's Jay Bhogaita, Business Director, reports

Trending Articles

  1. How to avoid sticking and picking in the tableting industry John Norman and Kevin Queensen of Natoli Engineering explain
  2. Peak identification by LC/MS: Automation versus analyst High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
  3. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  4. The modularisation of chemical API synthesis The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers
  5. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all